Osmofundin N (Mannitol)

Mannitol, the active ingredient in Osmofundin N, is an osmotic diuretic presented as a 20% solution for intravenous use. It is employed to reduce intracranial pressure and to promote diuresis in patients with renal impairment. GNH USA supplies Osmofundin N as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

GNH USA supplies Osmofundin N as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Osmofundin N is an osmotic diuretic that acts on fluid balance pathways in the body. - Cerebral edema: helps reduce intracranial pressure and cerebral swelling. - Acute kidney injury: facilitates renal excretion of water and electrolytes. - Glaucoma surgery: used intra‑operatively to lower intra‑ocular pressure. - Drug intoxication: aids in renal clearance of certain toxins. - Hyperkalemia management: supports removal of excess potassium through increased urine output.

Adverse reactions to mannitol are reported across a range of severity.

Common Side Effects: - Headache: mild to moderate discomfort. - Nausea: occasional upset stomach. - Electrolyte imbalance: mild changes in sodium or potassium levels. - Transient hypertension: short‑term rise in blood pressure. - Volume overload: signs of fluid retention.

Serious or Rare Side Effects: - Acute renal failure: sudden loss of kidney function. - Pulmonary edema: fluid accumulation in the lungs. - Severe hyponatremia or hypernatremia: dangerous shifts in sodium concentration. - Anaphylactoid reaction: rare allergic‑type response. - Cardiac arrhythmia: abnormal heart rhythm linked to electrolyte shifts.

When using Osmofundin N, clinicians should observe several safety measures. - Renal function monitoring: assess creatinine and urine output regularly. - Cardiovascular status: watch for signs of fluid overload or hypertension. - Electrolyte surveillance: check serum sodium and potassium frequently. - Infusion rate control: administer slowly to avoid rapid plasma osmolar shifts. - Contraindications review: avoid in patients with severe pulmonary edema or active intracranial hemorrhage. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Mannitol may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Loop diuretics: combined use can precipitate severe electrolyte disturbances. - Nephrotoxic antibiotics: increased risk of acute kidney injury. - Vasopressors: may blunt intended blood‑pressure effects.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance hypotensive response. - Lithium: altered renal clearance can raise lithium levels. - Insulin: rapid shifts in plasma volume may affect glucose control.